Highlights Fate Therapeutics, Inc.

Equities

FATE

US31189P1021

Real-time Estimate Cboe BZX Other stock markets 02:18:05 2024-04-29 pm EDT			5-day change	1st Jan Change
4.05 ^USD	+6.58%		-14.54%	+9.22%

Apr. 22	Fate Therapeutics, Inc. Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting	CI
Mar. 21	Fate Therapeutics, Inc. announced that it has received $19.996366 million in funding from Redmile Group, LLC	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fate Therapeutics, Inc. Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting	Apr. 22	CI
Fate Therapeutics Prices $100 Million Offering, Private Placement	Mar. 19	MT
Fate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26	CI
Earnings Flash (FATE) FATE THERAPEUTICS Posts Q4 Revenue $1.7M, vs. Street Est of $1.5M	Feb. 26	MT
Fate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 26	CI
Fate Therapeutics, Inc. Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors	Jan. 08	CI
Fate Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Fate Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Earnings Flash (FATE) FATE THERAPEUTICS Reports Q2 Revenue $0.9M, vs. Street Est of $5.7M	23-08-08	MT
Fate Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-03	CI
Fate Therapeutics, Inc. Provides Earnings Guidance for the Year 2023	23-05-03	CI
Earnings Flash (FATE) FATE THERAPEUTICS Posts Q1 Revenue $59M	23-05-03	MT
Fate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
Earnings Flash (FATE) FATE THERAPEUTICS Reports Q4 Revenue $44.4M	23-02-28	MT
Fate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-28	CI
North American Morning Briefing : Stock Futures Soft as Investors Eye Jobs Report	23-01-06	DJ
Fate Therapeutics, Inc. Receives Notice of Termination from Janssen Biotech,Inc. of the Collaboration and Option Agreement Dated April 2, 2020	23-01-05	CI
Fate Therapeutics Announces Clinical Safety and Activity Data of First-Ever iPSC-Derived Car T-Cell Therapy	22-12-10	CI
Fate Therapeutics, Inc. and Ono Pharmaceutical Co., Ltd. Enters into Letter Agreement in Connection with the Collaboration and Option Agreement	22-11-07	CI
Fate Therapeutics Says ONO Pharmaceutical Exercises Option to Product Candidate for Solid Tumors	22-11-07	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Fate Therapeutics, Inc.

Equities

FATE

US31189P1021

Highlights

Filters